MadeAi: From Regulatory Bottleneck to Strategic Accelerator in AI-Driven Life Sciences

Overview: How MadeAi's AI-Driven Evidence and Regulatory Platform Transforms Life Sciences

MadeAi is an evidence and regulatory AI platform designed to help life sciences organisations manage the growing volume and complexity of literature‑driven and submission‑grade documents. In areas such as clinical and scientific evidence synthesis, regulatory dossiers, and market access materials, teams are often constrained by manual review, fragmented source documents, and the need to keep narratives aligned with constantly evolving data and guidance. MadeAi aims to reduce this bottleneck by providing a structured environment where users can search, organise, and reuse underlying evidence while drafting and maintaining high‑stakes documents.

At a data level, the platform focuses on ingesting and structuring scientific publications, clinical data, and internal reference materials so they can be queried, linked, and traced back from individual claims in a document. AI models are then used to assist with tasks such as identifying relevant sources, generating draft text, and highlighting inconsistencies or gaps for human review, rather than replacing expert judgement outright. For regulatory, medical writing, and evidence teams, this can translate into shorter turnaround times for updates, more consistent use of supporting data across documents, and clearer traceability between source evidence and final narratives, helping organisations scale their documentation workload without losing control over quality or compliance standards.

What is MadeAi?

MadeAi is an evidence and regulatory AI platform that helps life sciences and pharma teams search, organise, and reuse scientific and clinical literature when creating or updating high‑stakes documents such as regulatory submissions, value dossiers, and other evidence packages. It is aimed at regulatory affairs, medical writing, market access, and evidence/HEOR teams that need to keep complex narratives aligned with underlying data and evolving guidelines. Its differentiation lies in treating source evidence as a first‑class asset with structured traceability from claims back to references, and in embedding AI into document workflows under human review rather than as a standalone text generator, supporting compliance and auditability in regulated environments.

Why Leading Healthcare Teams Trust MadeAi

• MadeAi is developed and operated by CapeStart, an established AI services and solutions firm focused on life sciences and pharma use cases.

• The platform has been built in partnership with multiple large pharmaceutical manufacturers, including top‑20 companies, indicating close alignment with real-world regulatory and evidence workflows.

• MadeAi has won multiple external awards, including Stevie Awards in the International Business Awards for AI/ML Solution in Healthcare, a PM360 Innovator recognition in the Generative AI category, and a Business Intelligence Group Artificial Intelligence Excellence Award.

• The MadeAi‑LR component is described as supporting systematic literature reviews and evidence synthesis in line with FDA and EMA requirements for SLR submissions, positioning it for regulated evidence workflows.

• The platform emphasises a human‑in‑the‑loop approach, with expert validation layered on top of GenAI outputs, to maintain accuracy, transparency, and traceability for risk‑sensitive tasks.

• MadeAi is positioned as providing a central repository with visibility into each workflow step and explicit transparency on inclusion and exclusion decisions in evidence review, supporting auditability.

• CapeStart highlights compliance-aware design for life sciences, focusing on traceable workflows, content provenance, and expert oversight rather than fully autonomous document generation.

• The product has been showcased at sector conferences such as ISPOR, signalling engagement with health economics, outcomes research, and market access communities that operate under formal methodological and regulatory expectations.